Endovia Health Sciences, Inc. (NYSE:EDVA) ("Endovia" or the "Company"), an emerging cannabinoid-based health sciences company, today welcomed recent developments in the federal marijuana rescheduling process, including the position advanced by the federal government during the Drug Enforcement Administration’s ("DEA") recent administrative hearings supporting the proposed transfer of marijuana from Schedule I to Schedule III of the Controlled Substances Act.

The Company believes the federal government’s affirmative support for Schedule III represents a significant evolution in U.S. cannabinoid policy and provides an increasingly clear signal that the federal government is moving toward a long-term regulatory framework that recognizes the medical potential of cannabinoids while maintaining appropriate federal oversight.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.